Study of Ataluren (PTC124™) in Cystic Fibrosis

This study has been completed.
Sponsor:
Collaborator:
Cystic Fibrosis Foundation
Information provided by (Responsible Party):
PTC Therapeutics
ClinicalTrials.gov Identifier:
NCT00803205
First received: December 4, 2008
Last updated: August 14, 2013
Last verified: August 2013
  Purpose

Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that makes the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A specific type of mutation called a nonsense (premature stop codon) mutation is the cause of CF in approximately 10% of subjects with the disease. Ataluren (PTC124) is an orally delivered investigational drug that has the potential to overcome the effects of the nonsense mutation. This study is a Phase 3 trial that will evaluate the clinical benefit of ataluren (PTC124) in adult and pediatric patients with CF due to a nonsense mutation. The main goals of the study are to understand whether ataluren (PTC124) can improve pulmonary function and whether the drug can safely be given for a long period of time. The study will also assess the effects of ataluren on CF pulmonary exacerbation frequency, cough frequency, health-related quality of life, antibiotic use for CF-related infections, CF-related disruptions to daily living, body weight, and CF pathophysiology. Funding Source - FDA OOPD


Condition Intervention Phase
Cystic Fibrosis
Drug: Ataluren (PTC124)
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

Resource links provided by NLM:


Further study details as provided by PTC Therapeutics:

Primary Outcome Measures:
  • Forced expiratory volume in 1 second (FEV1) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pulmonary exacerbation frequency [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Cough frequency [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Respiratory HRQL as assessed by the CFQ-R respiratory domain [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Forced vital capacity (FVC) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Safety profile [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • Compliance with study drug administration [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • Ataluren (PTC124) pharmacokinetics [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Antibiotic use and hospitalization due to CF-related symptoms [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Disruptions to school or work due to CF-related symptoms [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Body weight [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Markers of lung inflammation [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Lung computerized tomography CF score [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Nasal transepithelial potential difference (TEPD) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Sweat chloride concentration [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

Enrollment: 238
Study Start Date: July 2009
Study Completion Date: October 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ataluren (PTC124) Drug: Ataluren (PTC124)
10-, 10-, 20-mg/kg TID at morning, midday, and evening doses
Other Name: PTC124
Placebo Comparator: Placebo Drug: Placebo
Placebo

Detailed Description:

This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study, designed to document the clinical benefit of ataluren (PTC124) when administered as therapy of patients with CF due to a nonsense mutation (premature stop codon) in the CFTR gene. It is planned that ~208 subjects who are ≥6 years of age and have an FEV1 ≥40% and ≤90% of predicted will be enrolled. Study subjects will be enrolled at sites in North America, Europe, and Israel. They will be randomized in a 1:1 ratio to either ataluren (PTC124) or placebo. Subjects will receive study drug 3 times per day (at morning, midday, and evening) for 48 weeks. Subjects will be evaluated at clinic visits every 8 weeks. Additional safety laboratory testing, which may be performed at the investigational site or at an accredited local laboratory or clinic, is required every 4 weeks for the first 6 months of study participation. At the completion of blinded treatment, all compliant participants will be eligible to receive open-label ataluren (PTC124) in a separate extension study.

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to provide written informed consent (parental/guardian consent and subject assent if <18 years of age)
  • Age ≥6 years
  • Body weight ≥16 kg
  • Abnormal nasal TEPD total chloride conductance (a less electrically negative value than -5 mV for total chloride conductance [Δchloride-free+isoproterenol])
  • Sweat chloride >40 mEq/L
  • Documentation of the simultaneous presence of a nonsense mutation in at least 1 allele of the CFTR gene and a CF-causing mutation in the other CFTR allele, as determined by gene sequencing from a laboratory certified by the College of American Pathologists (CAP), or under the Clinical Laboratory Improvement Act/Amendment (CLIA), or by an equivalent organization
  • Verification that a blood sample has been drawn for confirmation of the presence of a nonsense mutation in the CFTR gene
  • Ability to perform a valid, reproducible spirometry test using the study-specific spirometer with demonstration of an FEV1 ≥40% and ≤90% of predicted for age, gender, and height
  • Resting oxygen saturation (as measured by pulse oximetry) ≥92% on room air
  • Documentation by VivoMetrics that the subject has satisfactorily completed a 24-hour LifeShirt® cough frequency assessment
  • Confirmed screening laboratory values within the central laboratory ranges (hepatic, adrenal, renal, serum electrolytes, and reproduction [women only] parameters)
  • In subjects who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and 4-week follow-up period
  • Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures

Exclusion Criteria:

  • Known hypersensitivity to any of the ingredients or excipients of the study drug
  • Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or reinitiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior to start of study treatment
  • Exposure to another investigational drug within 4 weeks prior to start of study treatment
  • Treatment with systemic aminoglycoside antibiotics at the time of the baseline TEPD assessment
  • Treatment with intravenous antibiotics within 3 weeks prior to start of study treatment
  • History of solid organ or hematological transplantation
  • Ongoing immunosuppressive therapy (other than corticosteroids)
  • Ongoing warfarin, phenytoin, or tolbutamide therapy
  • Ongoing participation in any other therapeutic clinical trial
  • Major complications of lung disease (including massive hemoptysis, pneumothorax, or pleural effusion) within 8 weeks prior to start of study treatment
  • Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 3 weeks prior to randomization
  • Known portal hypertension
  • Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test
  • Pregnancy or breast-feeding
  • Current smoker or a smoking history of ≥10 pack-years (number of cigarette packs/day x number of years smoked)
  • Prior or ongoing medical condition (eg, concomitant illness, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00803205

  Show 37 Study Locations
Sponsors and Collaborators
PTC Therapeutics
Cystic Fibrosis Foundation
Investigators
Study Director: Temitayo Ajayi, MD PTC Therapeutics
  More Information

No publications provided by PTC Therapeutics

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: PTC Therapeutics
ClinicalTrials.gov Identifier: NCT00803205     History of Changes
Other Study ID Numbers: PTC124-GD-009-CF, Orphan Product Grant #FD003715
Study First Received: December 4, 2008
Last Updated: August 14, 2013
Health Authority: Canada: Health Canada
European Union: European Medicines Agency
Israel: Ministry of Health
United States: Food and Drug Administration

Keywords provided by PTC Therapeutics:
Cystic fibrosis
Nonsense mutation
Premature stop codon
PTC124
Ataluren

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 21, 2014